- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Aliso Viejo Today
By the People, for the People
SpyGlass Pharma Completes $172.5M IPO
Late-stage biopharmaceutical company raises funds to advance novel eye drug delivery platform
Published on Feb. 9, 2026
Got story updates? Submit your updates here. ›
SpyGlass Pharma, Inc., a late-stage biopharmaceutical company focused on transforming the treatment of chronic eye conditions, has announced the closing of its initial public offering. The company raised $172.5 million in gross proceeds by selling 10,781,250 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares. SpyGlass Pharma's shares began trading on the Nasdaq Global Select Market under the ticker symbol 'SGP' on February 6, 2026.
Why it matters
The successful IPO provides SpyGlass Pharma with the capital needed to advance its novel, non-bioerodible drug delivery platform designed to treat a range of chronic eye conditions. The company's technology aims to significantly improve patient outcomes by enabling long-term, sustained drug delivery of approved medicines.
The details
The IPO was led by joint book-running managers Jefferies, Leerink Partners, Citigroup, and Stifel. SpyGlass Pharma plans to use the proceeds to fund the continued development and potential commercialization of its proprietary drug delivery platform, which can be used with various well-established, approved eye medications.
- SpyGlass Pharma's common stock began trading on the Nasdaq Global Select Market under the ticker symbol 'SGP' on February 6, 2026.
- The company announced the closing of its initial public offering on February 9, 2026.
The players
SpyGlass Pharma, Inc.
A late-stage biopharmaceutical company dedicated to transforming the treatment of chronic eye conditions through its novel, non-bioerodible drug delivery technology.
Malik Y. Kahook, M.D.
Co-founder of SpyGlass Pharma and a professor at the University of Colorado Anschutz School of Medicine, where the company's drug delivery platform was originally developed.
Glenn Sussman
Co-founder of SpyGlass Pharma, who, along with Dr. Kahook, founded the company to address the lack of durable treatment options for chronic eye conditions.
What’s next
SpyGlass Pharma plans to use the proceeds from the IPO to fund the continued development and potential commercialization of its proprietary drug delivery platform.
The takeaway
The completion of SpyGlass Pharma's $172.5 million IPO marks a significant milestone for the company as it seeks to transform the treatment of chronic eye conditions through its innovative drug delivery technology. The infusion of capital will enable the company to advance its platform and potentially bring new, long-lasting treatment options to patients in need.
